GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (OTCPK:AGRX) » Definitions » ROIC %

Agile Therapeutics (Agile Therapeutics) ROIC % : -341.36% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Agile Therapeutics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Agile Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -341.36%.

As of today (2024-05-14), Agile Therapeutics's WACC % is 32.17%. Agile Therapeutics's ROIC % is -372.84% (calculated using TTM income statement data). Agile Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Agile Therapeutics ROIC % Historical Data

The historical data trend for Agile Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agile Therapeutics ROIC % Chart

Agile Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -124.13 -289.04 -269.91 -175.13 -437.44

Agile Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -458.99 -462.54 -350.20 -279.79 -341.36

Competitive Comparison of Agile Therapeutics's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agile Therapeutics's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Agile Therapeutics's ROIC % falls into.



Agile Therapeutics ROIC % Calculation

Agile Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-19.884 * ( 1 - 0% )/( (5.462 + 3.629)/ 2 )
=-19.884/4.5455
=-437.44 %

where

Agile Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-16.208 * ( 1 - 0% )/( (5.867 + 3.629)/ 2 )
=-16.208/4.748
=-341.36 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agile Therapeutics  (OTCPK:AGRX) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Agile Therapeutics's WACC % is 32.17%. Agile Therapeutics's ROIC % is -372.84% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Agile Therapeutics ROIC % Related Terms

Thank you for viewing the detailed overview of Agile Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Agile Therapeutics (Agile Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
500 College Road East, Suite 310, Princeton, NJ, USA, 08540
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Executives
Scott M Coiante officer: Chief Financial Officer 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Josephine Torrente director 101 POOR FARM ROAD, PRINCETON NY 08540
Sandra Carson director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
John W Hubbard director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Amy Welsh officer: Chief Commercial Officer 500 COLLEGE ROAD EAST, SUITE 310, C/O AGILE THERAPEUTICS, INC., PRINCETON NJ 08540
Alfred Altomari director, officer: Chief Executive Officer C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Dennis Reilly officer: Chief Financial Officer 600 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jason Butch officer: Principal Accounting Officer 101 POOR FARM ROAD, PRINCETON NJ 08540
Paul Korner officer: Sr. VP & Chief Medical Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abhijeet J Lele director, See remarks C/O EP MEDYSTEMS, 575 RTE 73 N, WEST BERLIN NJ 08091
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003